Successful treatment of B cell prolymphocytic leukemia by fludarabine, cyclophosphomide and rituximab therapy: own experience and literature review
10.3760/cma.j.issn.1009-9921.2013.02.009
- VernacularTitle:RFC方案治疗B细胞幼淋巴细胞白血病一例并文献复习
- Author:
Yanru ZHANG
;
Zengjun LI
;
Junyuan QI
;
Lugui QIU
- Publication Type:Journal Article
- Keywords:
Leukemia,prolymphocytic,B cell;
Rituximab;
Purine nucleoside analogues;
Complete immunophenotypical response
- From:
Journal of Leukemia & Lymphoma
2013;22(2):91-93,97
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the clinical characteristics of B cell prolymphocytic leukemia (B-PLL).Methods The clinical manifestation,treatment and outcome of a 33-year-old man with B-PLL were reported.Results The young patient had thrombocytopenia and systemic B-symptoms,markedly raised lymphocyte'count,bulky splenomegaly and lymphadenopathy.He refused stem cell transplant,so RFC regimen (fludarabine,cyclophosphomide and rituximab) therapy were administered.After 4 cycles of RFC therapy,the patient achieved a complete immunophenotypical and hematological remission response.Conclusion RFC therapy might be a feasible and useful treatment option for B-PLL.
